Drugs Made in America Acquisition (DMAAU) Competitors $10.60 +0.10 (+0.95%) As of 08/22/2025 03:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock DMAAU vs. ONCHU, ASPCU, AGBAW, AGNCP, AGNCO, AGNCN, AGNCM, AGNCL, ANSCW, and ANSCUShould you be buying Drugs Made in America Acquisition stock or one of its competitors? The main competitors of Drugs Made in America Acquisition include 1RT Acquisition (ONCHU), A SPAC III Acquisition (ASPCU), AGBA Group (AGBAW), AGNC Investment (AGNCP), AGNC Investment (AGNCO), AGNC Investment (AGNCN), AGNC Investment (AGNCM), AGNC Investment (AGNCL), Agriculture & Natural Solutions Acquisition (ANSCW), and Agriculture & Natural Solutions Acquisition (ANSCU). These companies are all part of the "trading" industry. Drugs Made in America Acquisition vs. Its Competitors 1RT Acquisition A SPAC III Acquisition AGBA Group AGNC Investment AGNC Investment AGNC Investment AGNC Investment AGNC Investment Agriculture & Natural Solutions Acquisition Agriculture & Natural Solutions Acquisition 1RT Acquisition (NASDAQ:ONCHU) and Drugs Made in America Acquisition (NASDAQ:DMAAU) are both investment offices industry companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Which has stronger valuation and earnings, ONCHU or DMAAU? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio1RT AcquisitionN/AN/AN/AN/AN/ADrugs Made in America AcquisitionN/AN/AN/AN/AN/A Does the media favor ONCHU or DMAAU? In the previous week, Drugs Made in America Acquisition had 2 more articles in the media than 1RT Acquisition. MarketBeat recorded 2 mentions for Drugs Made in America Acquisition and 0 mentions for 1RT Acquisition. Drugs Made in America Acquisition's average media sentiment score of 0.40 beat 1RT Acquisition's score of 0.00 indicating that Drugs Made in America Acquisition is being referred to more favorably in the news media. Company Overall Sentiment 1RT Acquisition Neutral Drugs Made in America Acquisition Neutral Is ONCHU or DMAAU more profitable? Company Net Margins Return on Equity Return on Assets 1RT AcquisitionN/A N/A N/A Drugs Made in America Acquisition N/A N/A N/A SummaryDrugs Made in America Acquisition beats 1RT Acquisition on 2 of the 2 factors compared between the two stocks. Get Drugs Made in America Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAAU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAAU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAAU vs. The Competition Export to ExcelMetricDrugs Made in America AcquisitionInvestment Offices IndustryFinance SectorNASDAQ ExchangeMarket CapN/A$191.05M$12.40B$9.58BDividend YieldN/AN/A5.52%4.10%P/E RatioN/AN/A19.3926.04Price / SalesN/AN/A26.07102.77Price / CashN/A36,784.7921.7558.48Price / BookN/AN/A2.356.61Net IncomeN/A-$160K$1.01B$265.56M7 Day PerformanceN/A0.46%1.73%1.97%1 Month Performance0.95%0.45%1.02%-0.36%1 Year PerformanceN/A8.53%537.30%19.03% Drugs Made in America Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMAAUDrugs Made in America AcquisitionN/A$10.60+1.0%N/AN/A$0.00N/A0.002News CoverageONCHU1RT AcquisitionN/A$10.47-0.2%N/AN/A$0.00N/A0.002ASPCUA SPAC III AcquisitionN/A$10.35flatN/AN/A$0.00N/A0.00N/AAGBAWAGBA GroupN/A$0.04-38.3%N/A-83.1%$0.00$38.55M0.00152Gap DownAGNCPAGNC InvestmentN/A$25.28+0.3%N/A+5.0%$0.00$496M0.0050AGNCOAGNC InvestmentN/A$25.55+0.1%N/A+2.2%$0.00$496M0.0050AGNCNAGNC InvestmentN/A$25.84-0.2%N/A+0.0%$0.00$496M0.0050News CoverageAGNCMAGNC InvestmentN/A$25.19-0.6%N/A-0.8%$0.00$496M0.0050Positive NewsAGNCLAGNC InvestmentN/A$25.31+0.8%N/A+5.3%$0.00$496M0.0050ANSCWAgriculture & Natural Solutions AcquisitionN/A$0.24+4.3%N/A+66.7%$0.00N/A0.00N/AGap UpHigh Trading VolumeANSCUAgriculture & Natural Solutions AcquisitionN/A$11.00-5.5%N/AN/A$0.00N/A0.00N/A Related Companies and Tools Related Companies 1RT Acquisition Competitors A SPAC III Acquisition Competitors AGBA Group Competitors AGNC Investment Competitors AGNC Investment Competitors AGNC Investment Competitors AGNC Investment Competitors AGNC Investment Competitors Agriculture & Natural Solutions Acquisition Competitors Agriculture & Natural Solutions Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAAU) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Drugs Made in America Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Drugs Made in America Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access